<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Veer Jaradi on Medium]]></title>
        <description><![CDATA[Stories by Veer Jaradi on Medium]]></description>
        <link>https://medium.com/@veerjaradi?source=rss-91f4a31e8f14------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*mOmRe9k2sFb3oGfVdX7d9g.png</url>
            <title>Stories by Veer Jaradi on Medium</title>
            <link>https://medium.com/@veerjaradi?source=rss-91f4a31e8f14------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 05:42:31 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@veerjaradi/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Replicating Modular CRISPR Targets Using Open Source Genomic Data]]></title>
            <link>https://medium.com/@veerjaradi/replicating-modular-crispr-targets-using-open-source-genomic-data-712bbcb6874f?source=rss-91f4a31e8f14------2</link>
            <guid isPermaLink="false">https://medium.com/p/712bbcb6874f</guid>
            <category><![CDATA[crispr]]></category>
            <category><![CDATA[biotech]]></category>
            <category><![CDATA[gene-editing]]></category>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[huntingtons-disease]]></category>
            <dc:creator><![CDATA[Veer Jaradi]]></dc:creator>
            <pubDate>Thu, 05 Nov 2026 14:42:47 GMT</pubDate>
            <atom:updated>2026-11-05T14:42:47.321Z</atom:updated>
            <content:encoded><![CDATA[<p>It’s one thing to read about neurogenomics in a textbook, and another to stare at real patient allele data on a screen, which completely alters your perception on genetic medicine.</p><p>Huntington’s disease has always been an inescapable, neurodegenrative disorder inheritied at birth. A single mutated gene quietly degrading the central nervous system over decades.</p><p>When regular, standard CRISPR emerged, everyone in the industry beleived we had found our universal cure. But the brain, like it always does, presented a terrifying catch: knocking out the mutated mHTT gene which causes the disease also accidently wipes out the healthy, wtHTT copy, which is crucial for neurological and physiological function.</p><p>In my previous article, I explored how PAM-Altering SNP’s are being used by scientists to solve this bottleneck. These are tiny, single letter variations that mark the chromosome that is mutant. When we target a sequence that has this single letter swap, it creates a functional PAM site (which for SpCas9 is NGG) on the mutated allele while leaving a non functional sequence (NGA) on the wild type allele, which means that total selectivity is achieved, full activity on the mutant gene while the wild type one is completely preserved.</p><p>The research was conducted on this initially. Now I aim to work with real genomic data to see how it’s translated to real patient populations, which is a completely different challenge. That led me into creating something new: My Replicate Project.</p><h3>The Problem I Wanted to Explore</h3><p>In the midst of my research, I stumbled upon a major debate in neurogenomics. I explored this more in depth in my learn article, but it was essentially how traditional pharmaceutical labs constantly propose a “one size fits all” drug to maximise economical efficiency and market size. When applied to PAM-Altering SNP’s however, targeting a well known SNP site like rs363099 only covers 38% of people of european descent.</p><p>This leads to the emergence of a massive structural challenge: How do we make allele-specific gene therapy viable without forcing a dangerous and non-selective knockdown drug onto the remaining 62% of patients?</p><p>This was my hot take:</p><p><strong><em>Instead of chasing an impossible universal guide RNA, platforms should deploy a modular panel of 3 to 4 targeted guide RNAs off the shelf, which would cover most of the patient population while still utilising the same delivery method.</em></strong></p><p>By using open source scientific data, I wanted to prove this mathematically — Mapping real SNP locations across the HTT gene and calculating how top variant targets impacts the overall coverage of the patient population.</p><h3>Under the Hood of the Open Source Dataset</h3><p>I went straight to GitHub and tapped into the <strong>WGLab/HTT-SNP-Phasing</strong> repository, which is a publicly available genomic reference dataset containing the exact SNP’s linked to the HTT gene.</p><p>Google Sheets was used as my primary workspace, where i structured raw reference data across these key variables:</p><ul><li>Genomic Position (GRCh38 assembly): The precise base pair coordinate along Chromosome 4 where each variation occurs.</li><li>Allele Profiles: Tracking the reference vs. alternative nucleotide substitutions (for example, C to T, G to A).</li><li>PAM Creation Status: Identifying whether the sequence modification creates a functional NGG docking site required for SpCas9 binding.</li><li>Population Coverage Metrics: Individual frequency rates for major target variants across patient cohorts.</li></ul><h3><strong>Building the Replicate</strong></h3><p>Transforming these raw genomic coordinates into a portfolio that would deemed as scientific required breaking down the process into clear, concise steps —</p><ol><li><strong>Data Ingestion &amp; Structuring:</strong> I extracted 10 representative SNP loci from the WGLab French cohort dataset which ranged from Exon 1 down through Exon 29 and organized them into a structured sheet.</li><li><strong>Genomic Mapping:</strong> I plotted physical genomic positions against each SNP ID to build a visual map of where these variations sit along Chromosome 4.</li><li><strong>Coverage Analysis:</strong> By isolating key PAM-creating target sites (rs363099, rs2857935, and rs16843804), I mapped individual patient coverage percentages to demonstrate the incremental impact of each guide RNA.</li></ol><h3><strong>What the Data Showed</strong></h3><p>The resulting visual models brought the underlying biology to life:</p><blockquote>[Target: rs363099] → 38% Population Coverage</blockquote><blockquote>[Target: rs2857935] → +30% Cumulative Reach (approx 68%)</blockquote><blockquote>[Target: rs16843804] → +17% Cumulative Reach (approx 85%)</blockquote><blockquote>Result: 3-Guide Panel achieves ~85% Total Coverage while preserving wtHTT</blockquote><p>The data explicitly validated my thesis: While a single SNP like rs363099 covers less than 40% of patients by itself, layering only just 3 high frequency PAM-Altering targets into a modular panel scales the clinic coverage to approximately 85%</p><p>Because the underlying Cas9 enzyme, viral vector casing, and delivery systems all remain the same, clinicians could just simply run a quick sequence test and pull the corresponding guide RNA off the shelves (gRNA)</p><h3>What I Learned and What’s Next</h3><p>Building this replicate, it taught me that synthetic and computational biology doesn’t always require writing complicated lines of code from scratch. I worked with open source data directly from GitHub and transformed it into clear visual models, and by doing so I gained extremely valuable hands on experience regarding genomic coordinates, PAM requirements, and theraputic population modelling.</p><p>More importantly though, it ultimately proved that solving these complex biomedical problems isn’t about designing an overly intuitive molecular tool. It is primarily about strategically thinking with respect to how technology can be deployed safely and modularly for real people</p><h3>ABOUT THE AUTHOR</h3><p>My name is Veer, and I am an innovator at TKS Dubai. I am currently exploring the intersection between synthetic biology, neuroscience, and gene editing. I am passionate about turning complex biomedical research into engineering solutions that are actionable. On the side, I also like to explore kinesiology, analyze different papers and conduct experiments.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=712bbcb6874f" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Targeting PAM-Altering SNPs to Cure Huntington’s Disease]]></title>
            <link>https://medium.com/@veerjaradi/targeting-pam-altering-snps-to-cure-huntingtons-disease-92a605bff6e9?source=rss-91f4a31e8f14------2</link>
            <guid isPermaLink="false">https://medium.com/p/92a605bff6e9</guid>
            <category><![CDATA[huntingtons-disease]]></category>
            <category><![CDATA[crispr]]></category>
            <category><![CDATA[neuroscience]]></category>
            <dc:creator><![CDATA[Veer Jaradi]]></dc:creator>
            <pubDate>Sun, 04 Oct 2026 17:15:48 GMT</pubDate>
            <atom:updated>2026-10-11T18:47:25.072Z</atom:updated>
            <content:encoded><![CDATA[<p>You’re sitting opposite a physician. They slide the DNA test result across the table. Eye contact is firm, and a modern death sentence is delivered. “Unfortunately, you have inherited the precise genetic sequence that will systematically disintegrate your nervous system over the next fifteen years.”</p><p>While the professionals never use such hyperbolic language, this is the exact translation that conjures up in my head whenever I think about a patient experience when receiving news that they have Huntingtons.</p><p>There is no escape. Every time a thumb twitches or groceries are forgotten in the car, a shock of cold panic hits them. “Are my brain cells dying now?”</p><p>It was revolutionary when it emerged. CRISPR-Cas9. Humanity thought we had finally forged a great enough weapon on the molecular scale to erase inherited diseases deemed fatal once and for all. But when the scientists attempted to deploy a regular CRISPR inside the central nervous system of a human, they came face to face with a brutal biological paradox: knocking out the disease-causing gene in the brain can be just as brutal as just letting it sit there instead.</p><p>This brings us to the core challenge driving modern neurogenomics: How can we selectively suppress the mutant HTT allele without unnecessarily disrupting the essential healthy copy?</p><p>To actually treat Huntington’s without triggering systematic failure that scales above a major catastrophe, high precision, single letter genomic surgery must be performed.</p><p>Here is how we are exploiting PAM-Altering Single Nucleotide Polymorphisms (SNPs) to silence mutant genes while leaving healthy brain cells that are vital for function completely untouched.</p><p>Now, together, let’s dive into this topic.</p><h3><strong>Why Standard Knockdowns Fail</strong></h3><p>Huntington’s is an autosomal dominant disorder that is neurodegenerative. Located on chromosome 4, it is stemmed from a hyper expanded trinucleotide “CAG” sequence that is repeated in Exon 1 of the HTT gene (huntington).</p><p>Individuals affected by it inherit around 36 to well over a hundred of these repeats, while people who are unaffected carry 10 to 35. During ribosomal translation, these codons of CAG translate into a large polyQ (polyglutamine) chain at the front of the protein (N terminus) of the Huntington protein that is expressed.</p><blockquote>Healthy HTT Gene: [Exon 1: (CAG)18 ] — — → Healthy Huntingtin Protein (Normal Function)</blockquote><blockquote>Mutant mHTT Gene: [Exon 1: (CAG)48+] — — → Misfolded PolyQ Protein (Toxic Aggregates)</blockquote><p>The large stretch caused by the codons causes the protein to fold in a wrong way which can then lead to it being broken down into toxic substances like toxic peptides. These misfolded proteins over time act as “cellular sludge”. This is because they can essentially suffocate or choke out axon signaling pathways in the brain that are vital for basic function and/or disrupt mitochondrial activity such as energy production. This can trigger a large wave of the death of spiny neurons in the cerebral cortex and striatum.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*QLlpcY76N1oOfOqniL-kvQ.png" /><figcaption>Figure 1: Cross-sectional comparison of a normal brain versus a Huntington’s disease brain showing basal ganglia atrophy and enlarged ventricles. Source: adapted from Medical Gallery of Blausen Medical, 2014.</figcaption></figure><h3><strong>The Human Genetic Catch</strong></h3><p>The problem gets tricky here. Humans, people like you and me, are creatures that are diploid, meaning two copies of almost every gene are inherited (alleles). One from the mother and one from the father. In a patient with Huntington’s only one of the inherited copies carries the mutation (mHTT) discussed earlier, while the second copy is perfectly normal (wtHTT).</p><p>The healthy copy is not just some DNA that contains no purpose. It is vital and acts as a maintenance worker for the brain. It is required for the following critical biological functions:</p><ul><li><strong>Axonal Neurotrophic Transport: controlling the physical movement of vesicles containing Brain-Derived Neurotrophic Factor which is essential for cell function along the axon to keep striatal neurons alive.</strong></li><li><strong>Transcriptional Regulation: Binding to specific nuclear factors to maintain normal gene expression programs across the central nervous system, to ensure it runs smoothly</strong></li><li><strong>Synaptic Integrity: Preventing cell death (anti-apoptotic signaling) and maintains the neurotransmitter communication between synapses</strong></li></ul><p>Therapeutic attempts that were conducted earlier tried to perform suppression. It used tools that were not selective to shutdown both the genes — wtHTT and mHTT simultaneously. While therapeutic intentions were presented during pan-suppression, safety concerns were raised regarding long term neurotoxicity and motor deficits in preclinical models because of complete wtHTT gene depletion (<a href="https://www.google.com/search?q=https://doi.org/10.1016/j.neuron.2012.03.021">Kordasiewicz et al., 2012</a>). On the other hand, recent preclinical evidence suggests a reality that is more nuanced. While the complete loss of wtHTT gene is dangerous, partial reduction of wtHTT has possibilities to be tolerated in certain adult models. (<a href="https://www.google.com/search?q=https://doi.org/10.1038/s41531-020-00124-0">Wang et al., 2020</a>). Even if reducing the gene partially is an option, preservation of the wild type allele is still the safest, gold standard.</p><h3><strong>Targeting Allele-Specific SNPs for Safer Gene Therapy</strong></h3><p>For CRISPR to cut the harmful allele while the healthy one is left at peace, the scientists need to look at sequence variations that are specific to the allele.</p><p>Outside the CAG repeat area, the wtHTT and mHTT alleles both look identical. However, the population of the human species carry many (millions) of natural single letter genetic variants</p><p>Throughout their genomes and these are known as Single Nucleotide Polymorphisms (SNPs). As generations progress, these SNPs are inherited alongside the CAG expansion that causes the disease.</p><p>To help put this into perspective, I like to use an analogy — the little genetic variations act essentially as a molecular “beacon” of some sort which mark the mutant chromosome</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/876/1*SWWoiT0Ipz5DrbkeHoO1Xg.png" /><figcaption>Figure 2: Allele-specific targeting via PAM-altering SNPs. Source: adapted from Wu et al., 2020.</figcaption></figure><h3><strong>Leveraging PAM Requirements for Selective Targeting</strong></h3><p>Streptococcus pyogenes Cas9 (SpCas9) cannot just bind to any random DNA sequence it likes. It has a requirement. A 3 letter genomic sequence that needs to be directly adjacent to the 20-nucleotide guide RNA (gRNA) target site. This is what is known as the Protospacer Adjacent Motif (PAM), as explained above which is essentially a docking site. For SpCas9 specifically, the PAM is NGG. The N is a place holder so it can be any base, followed up by two guanines.</p><p>If the 20 nucleotide guide RNA is exactly the same as the cell’s DNA sequence, the SpCas9 cannot physically latch onto the DNA and cut it, if the NGG PAM sequence is not present.</p><blockquote>Mutant Allele (mHTT): [Target Sequence (20bp)] — N G G — -&gt; Cas9 Binds &amp; Cuts</blockquote><blockquote>Healthy Allele (wtHTT): [Target Sequence (20bp)] — N G A — -&gt; Cas9 Ignored</blockquote><p>By locating PAM-Altering SNPs (PAS), it points in the genome where a single letter substitution has created a functional “docking site” (as we talked about before) which is the NGG PAM site on the mutant chromosome. It also leaves a sequence that is non functional like NGA or NGC on the normal, unharmed chromosome (<a href="https://www.nature.com/articles/nrneurol.2016.151">Malkki, 2016</a>). This means that researchers and scientists can restrict SpCas9 chemical cutting to purely the disease inflicting allele.</p><h3><strong>Molecular Mechanisms of Target Gene Silencing</strong></h3><p><strong>METHOD A: Nonsense Mediated Decay (NMD) via Single Indels</strong></p><p>When SpCas9 cuts the DNA inside a cell, Non-Homologous End Joining (NHEJ) (the cells emergency repair pathway) rushes to quickly glue back the broken ends of the DNA together. Because NHEJ is prone to making errors, it can routinely delete or insert a few new base pairs at the place where the DNA has been cut.</p><blockquote>Mutant DNA Cut — -&gt; Error-Prone Repair (Indel) — -&gt; Frameshift Mutation — -&gt; Premature Termination Codon (PTC) — -&gt; Nonsense-Mediated Decay (NMD) — -&gt; Toxic mRNA Destroyed.</blockquote><p>The insertion or deletion of the base pairs shifts the 3 letter reading frame of the gene out of alignment. This creates a Premature Termination Codon occurring earlier back in the sequence. The machinery of the cell that is responsible for its internal quality control, it detects the premature stop codon during the surveillance of mRNA which then leads to activation of Nonsense-Mediated mRNA Decay (NMD). Before it can ever reach a ribosome and produce the toxic protein polyQ, the cell systematically degrades the mutant mRNA.</p><p>By targeting specific loci like rs363099 which is located on exon 29, it allows the guide RNA to trigger NMD selectively on the transcript that is mutated without affecting wild type mRNA levels (<a href="https://doi.org/10.1172/jci.insight.141042">Shin et al., 2022</a>).</p><p><strong>Method B: Transcription-Prevention CRISPR (TP-CRISPR) via Dual Excision</strong></p><p>Instead of relying on the indel information which can be random, scientists can deploy TP-CRISPR by using two different guide RNAs which target two different PAM altering SNP sites, which in turn the locus causing the disease.</p><p>The molecular scissors, SpCas9, creates two double stranded cuts at the same time on the mutated chromosome, which snips out a massive amount (44 kilobase) of DNA fragment which contains the promoter or Exon 1. The cell then glues back the remaining fragments of DNA back together, which in turn permanently stops the transcription of the mutant gene directly at its genomic source (<a href="https://doi.org/10.1016/j.ymthe.2021.03.022">Monteys et al., 2021</a>).</p><h3><strong>Real-World Labs and Structural Engineering Challenges</strong></h3><p>The now slightly “challenging” part of this is translating this precise scientific endeavor into real time clinical action. Many biotechnology companies and academic labs are driving the technology of CRISPR to cure autosomal diseases.</p><ul><li><strong>The Davidson Lab (University of Iowa): Experts in the field of developing allele selective RNA interference to demonstrate functional recovery that is long term in mammals.</strong></li><li><strong>Synthego &amp; Editas Medicine: Constructing chemically modified synthetic guides RNAs which are highly accurate to spot a single letter DNA difference, and does not induce off target edits on regions that are non target genomes.</strong></li><li><strong>UniQure &amp; PTC Therapeutics: Advancing these gene therapy methods into actual clinical tests, where the data regarding safety shows that preserving wtHTT is crucial for neurological function and therapeutic success.</strong></li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*IJyNyVSGWibrfi6WG91lnA.png" /><figcaption>Figure 3: Comparison of genomic organization between wild-type AAV (rep and cap genes) and recombinant AAV vector constructs carrying a promoter, therapeutic transgene, and poly A tail flanked by ITRs. Source: adapted from Naso et al., 2017.</figcaption></figure><h3><strong>The Central Nervous System Delivery Bottleneck</strong></h3><p>A significant biomedical barrier is that getting the CRISPR tool inside millions of living human brain cells.</p><ul><li><strong>The Blood-Brain Barrier: Intravenous drug injections cannot pass through the endothelial wall that is tightly sealed of the central nervous system to reach the striatum which is located deep inside the brain</strong></li><li><strong>Viral Capacity Constraints: Adeno-Associated Virus Serotype 9 (AAV9) is the main viral vector which targets brain cells. AAVs essentially have a physical payload that is very strict, which is around 4.7 kilobases. A regular SpCas9 gene usually is 4.2 kilobases and when combined with guide RNA, cassettes, promoters, and polyA tails exceeds the payload limit</strong></li><li><strong>Immune Activation and Off Target Risks: Viral delivery highly compels the cells in the brain to produce Cas9 for years and years on end. This excess production of Cas9 can result in an increase of risk in regard to triggering an autoimmune response or making cuts that are accidental somewhere else in healthy DNA.</strong></li></ul><h3><strong>Next Generation Delivery Solutions</strong></h3><p>Researchers are building to very important technologies to overcome the constraints regarded with delivery.</p><p>1- Dual-AAV Reconstitution: They split the Cas9 gene into two separate halves (N terminal and C terminal) and also packaging them into two different and independent AAV9 vectors. They then use intein mediated trans-splicing to reassemble and “glue back” the fully active Cas9 enzyme</p><p>2- Self Inactivating CRISPR (sifCRISPR): They programme a secondary guide RNA into the DNA “backbone” of the viral vector. One Cas9 has successfully cut and destroyed the mHTT allele, it turns around and cuts itself its own expression plasmid. This shuts itself off permanently to prevent further long term and unintentional damage.</p><h3><strong>My Hot Take: We Need to Stop Chasing “One Size Fits All” Gene Therapies</strong></h3><p>Here is my main hot take regarding where the neurotherapeutic field is heading:</p><blockquote><strong>“Instead of searching for one universal Huntington’s CRISPR therapy, could a standardized panel of allele-specific guides cover different patient haplotypes while preserving the same delivery and manufacturing platform?”</strong></blockquote><p>No single SNP occurs in every single patient with Huntington’s. This is my main criticism directed at PAM altering SNPs. For instance, when targeting the rs363099 SNP site, it only covers around 30% — 48% of HD patients from european descent, while it leaves the rest of the 55% — 70% without a usable PAM sequence (<a href="https://doi.org/10.1172/jci.insight.141042">Shin et al., 2022</a>). The argument that stems from traditional pharmaceutical companies are that it is unviable in a financial manner to develop a drug that cannot treat an entire population with the disease at once.</p><p>This pharmaceutical perspective comes across as deeply flawed to me.</p><p>Just to purely maximize market sizes, it is not appropriate to attempt to force a single and non selective gene knockdown drug into every patient as it simply ignores basic biology. It is a simple representation on how corporate scale is much largely prioritised when compared to basic human safety. This results in many clinical trials that are halted due to severe neurotoxicity when the wtHTT allele is suppressed accidentally.</p><blockquote>Traditional Model: [Universal Non-Selective Drug] — -&gt; High Safety Risk / Trial Halts</blockquote><blockquote>Next-Gen Model: [Panel of 3–4 Allele-Selective gRNAs] — -&gt; Estimated ~80–85% Population Coverage + Preserved wtHTT</blockquote><p>It is absolute that we cannot chase a universal guide RNA. Instead of this, platforms should develop a modular panel that is standardized of 3 to 4 allele selective guide RNAs which target the most common disease haplotypes. ( <em>rs363099</em>, <em>rs2857935</em>, and <em>rs16843804</em>)</p><p>Clinicians can just run a quick genetic sequence of a patient with Huntingtons and pull the corresponding guide RNA off the shelf. This is because the underlying Cas9 enzyme, the viral vector casing, and the manufacturing pipelines remain identical across treatments.</p><p>Modeling suggests that combining just three targeted SNP guide RNAs could cover an estimated 80% to 85% of the Huntington’s patient population (<a href="https://www.google.com/search?q=https://doi.org/10.1038/mt.2009.68">Pfister et al., 2009</a>), providing precise allele specificity while leaving the vital <em>wtHTT</em> gene intact.</p><h3><strong>ABOUT THE AUTHOR</strong></h3><p>My name is Veer, and I am an innovator at TKS Dubai. I am currently exploring the intersection between synthetic biology, neuroscience, and gene editing. I am passionate about turning complex biomedical research into engineering solutions that are actionable. On the side, I also like to explore kinesiology, analyze different papers and conduct experiments.</p><p><strong>Works Cited</strong></p><ul><li>Lee, Jong-Min. ‘Complete Allele-Specific Silencing of the Gain-of-Function Mutation of Huntington’s Disease’. <em>Datadryad.Org</em>, 2022, <a href="https://doi.org/10.5061/dryad.1g1jwstsb/linkset">https://doi.org/10.5061/dryad.1g1jwstsb/linkset</a></li><li>Kordasiewicz, H. B., et al. (2012). “Sustained huntingtin lowering is well tolerated and delays disease progression in Huntington’s disease models.” <em>Neuron</em>, 74(6), 1031–1044.<a href="https://www.google.com/search?q=https://doi.org/10.1016/j.neuron.2012.03.021"> </a><a href="https://doi.org/10.1016/j.neuron.2012.03.021">https://doi.org/10.1016/j.neuron.2012.03.021</a></li><li>Malkki, H. (2016). “Selective Deactivation of Huntington Disease Mutant Allele by CRISPR–Cas9 Gene Editing.” <em>Nature Reviews Neurology</em>, 12(11), 614–615.<a href="https://www.nature.com/articles/nrneurol.2016.151"> https://www.nature.com/articles/nrneurol.2016.151</a></li><li>Merienne, N., et al. (2017). “Cell-Type-Specific Gene Genome Editing Outperforms Non-Selective Suppression in the CNS.” <em>Cell Stem Cell</em>, 20(5), 677–688.<a href="https://www.google.com/search?q=https://doi.org/10.1016/j.stem.2017.03.022"> </a><a href="https://doi.org/10.1016/j.stem.2017.03.022">https://doi.org/10.1016/j.stem.2017.03.022</a></li><li>Monteys, A. M., et al. (2021). “CRISPR/Cas9 editing of the mutant Huntingtin allele in Huntington’s disease.” <em>Molecular Therapy</em>, 29(5), 1800–1815.<a href="https://doi.org/10.1016/j.ymthe.2021.03.022"> https://doi.org/10.1016/j.ymthe.2021.03.022</a></li><li>Pfister, C. A., et al. (2009). “Five siRNA duplexes provide extensive coverage of mutant Huntingtin alleles in Huntington’s disease patients.” <em>Molecular Therapy</em>, 17(5), 871–877.<a href="https://www.google.com/search?q=https://doi.org/10.1038/mt.2009.68"> </a><a href="https://doi.org/10.1038/mt.2009.68">https://doi.org/10.1038/mt.2009.68</a></li><li>Shin, J. W., et al. (2022). “Allele-specific silencing of the gain-of-function mutation in Huntington’s disease using CRISPR-Cas9.” <em>JCI Insight</em>, 7(19), e141042.<a href="https://doi.org/10.1172/jci.insight.141042"> https://doi.org/10.1172/jci.insight.141042</a></li><li>Tornabene, P., et al. (2019). “Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina and brain.” <em>Science Translational Medicine</em>, 11(523), eaav4523.<a href="https://www.google.com/search?q=https://doi.org/10.1126/scitranslmed.aav4523"> </a><a href="https://doi.org/10.1126/scitranslmed.aav4523">https://doi.org/10.1126/scitranslmed.aav4523</a></li><li>Wang, N., et al. (2020). “Evaluating the safety profile of huntingtin-lowering strategies in adult models.” <em>NPJ Parkinson’s Disease</em>, 6, 18.<a href="https://www.google.com/search?q=https://doi.org/10.1038/s41531-020-00124-0"> https://doi.org/10.1038/s41531-020-00124-0</a></li></ul><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=92a605bff6e9" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>